Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
The Impact of New Weight Loss Drugs on Dietetics
The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
Weight loss drug industry injects wealth into Novo Nordisk home country
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great heft to the economy of Novo Nordisk's home country, Denmark.
Can new weight loss drugs delay ageing?
What is ageing? Ageing is a highly complex biological process. Our DNA is constantly being broken down and repaired. An imbalance in this process, leading to poor repair of DNA, is one of the hallmarks of ageing.
Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
Novo Nordisk aware of 10 deaths related to weight-loss drug copies - report
Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs Wegovy and Ozempic, its CFO Karsten Munk Knudsen told a media
Nature1d
How ‘miracle’ weight-loss drugs will change the world
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss ...
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
The weight-loss drug users and doctors whom The Times spoke to for this ... As powerful anti-obesity drugs become ...
Time on MSN2d
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
And research continues to uncover new and surprising potential uses for GLP-1s ... 37% of people using a GLP-1 drug for ...
Analysis-Americans Hungry for Weight-Loss Drugs Grapple With Supply and Insurance Hurdles
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
New Atlas6d
Popular weight-loss drugs cause wastage in vital skeletal muscle
Rapid weight loss can cause a greater loss of muscle mass than losing weight slowly. The popularity of newer weight-loss ...
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has ...
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...